MedTrace Logo

Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

NCT03345797 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-10-26

No results posted yet for this study

Summary

PK study to evaluate serum levels of testosterone post nasal delivery in two cohorts of hypogonadal boys.

Conditions

  • Hypogonadism

Interventions

DRUG

Testosterone Nasal Gel [Natesto]

nasal gel containing 4.5% w/w testosterone

Sponsors & Collaborators

  • Acerus Biopharma Inc.

    lead INDUSTRY

Principal Investigators

  • Syed Faisal Ahmed, MD · Royal Hospital for Children, U. of Glasgow

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-04-11
Completion
2022-04-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03345797 on ClinicalTrials.gov